Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Progression-free survival (PFS) of patients with lower-risk myelodysplastic syndromes (MDS) treated with red blood cell transfusions is usually reduced, but it is unclear whether transfusion dose density is an independent prognostic factor. The European MDS Registry collects prospective data at 6-mo...

Descripción completa

Detalles Bibliográficos
Autores principales: de Swart, Louise, Crouch, Simon, Hoeks, Marlijn, Smith, Alex, Langemeijer, Saskia, Fenaux, Pierre, Symeonidis, Argiris, Cermâk, Jaroslav, Hellström-Lindberg, Eva, Stauder, Reinhard, Sanz, Guillermo, Mittelman, Moshe, Holm, Mette Skov, Malcovati, Luca, Mądry, Krzysztof, Germing, Ulrich, Tatic, Aurelia, Savic, Aleksandar, Almeida, Antonio Medina, Gredelj-Simec, Njetocka, Guerci-Bresler, Agnes, Beyne-Rauzy, Odile, Culligan, Dominic, Kotsianidis, Ioannis, Itzykson, Raphael, van Marrewijk, Corine, Blijlevens, Nicole, Bowen, David, de Witte, Theo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049377/
https://www.ncbi.nlm.nih.gov/pubmed/31171638
http://dx.doi.org/10.3324/haematol.2018.212217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049377/
https://www.ncbi.nlm.nih.gov/pubmed/31171638
http://dx.doi.org/10.3324/haematol.2018.212217

Ejemplares similares